A Pilot Clinical Trial of Smoking Cessation Services Implemented in the Workplace for Service Industry Employees

American Journal of Health Promotion : AJHP
Krysten W BoldStephanie S O'Malley

Abstract

Evaluate the feasibility and preliminary efficacy of implementing evidence-based tobacco treatment at the workplace for service industry employees. Randomized trial using 6 paired worksites (3 test and 3 delayed intervention control sites). US Northeast city. Employees were recruited from university food service settings. Comprehensive smoking treatment was provided at the workplace including individual counseling, free pharmacotherapy (dual nicotine replacement therapy or varenicline), and 5 weeks of contingency management that reinforced abstinence or reductions in smoking to encourage progress toward quitting. Primary measures included a smoking status survey administered at the end of treatment at the test sites and before treatment began at the delayed intervention control sites. Analyses compared rates of quit attempts and successful abstinence for at least 24 hours between the test and delayed intervention control sites. Twenty-five employees were enrolled in treatment. The majority were single (12/25), black (16/25), and reported their educational attainment as high school or less (18/25). Employees in the test (vs delayed intervention control) sites reported higher rates of quit attempts (66.7% vs 12.5%, P = .02) and s...Continue Reading

References

Jan 1, 1986·Journal of Applied Behavior Analysis·M L StitzerA M Mead
Jan 1, 1982·Addictive Behaviors·M L Stitzer, G E Bigelow
Jul 27, 2002·BMJ : British Medical Journal·Caroline M Fichtenberg, Stanton A Glantz
Apr 13, 2004·Journal of Occupational and Environmental Medicine·Donald R ShoplandKaren K Gerlach
Feb 1, 2005·Addiction·Martin A JavorsRichard J Lamb
Nov 30, 2006·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·John R Hughes, Matthew J Carpenter
Jan 17, 2008·The American Journal of Psychiatry·Lissa DutraMichael W Otto
Jan 19, 2008·American Journal of Preventive Medicine·Saul ShiffmanJoseph G Gitchell
Mar 15, 2008·Addiction·Saul Shiffman, Stuart G Ferguson
Jul 12, 2008·American Journal of Preventive Medicine·UNKNOWN Clinical Practice Guideline Treating Tobacco Use and Dependence 2008 Update Panel, Liaisons, and Staff
Nov 22, 2008·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Terry M BushCathryn Cushing
Oct 13, 2011·Journal of Occupational and Environmental Medicine·David Cal HamBradley A Evanoff
Nov 30, 2011·Archives of Internal Medicine·Matthew J CarpenterAnthony J Alberg
Jan 9, 2014·JAMA : the Journal of the American Medical Association·Kate CahillTim Lancaster
Jun 4, 2014·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Karen L CropseyPeter S Hendricks
Dec 17, 2014·American Journal of Preventive Medicine·Xin XuTerry F Pechacek
Jan 15, 2016·Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco·Molly McCarthyMelissa Tibbits
Jan 6, 2017·MMWR. Morbidity and Mortality Weekly Report·Stephen BabbAhmed Jamal

❮ Previous
Next ❯

Citations

Jun 18, 2020·Tobacco Prevention & Cessation·Marie Chan Sun, Lovena Rathoa

❮ Previous
Next ❯

Methods Mentioned

BETA
pharmacotherapy

Software Mentioned

SmokeFreeTXT

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.